Kenvue is a consumer health company that makes and sells OTC medicines, skincare, and personal care products. Its brand portfolio includes some of the most recognized names in consumer health: Tylenol, Zyrtec, Benadryl, Motrin, and Nicorette in OTC health; Neutrogena, Aveeno, and OGX in skin and hair care; and Listerine, BAND-AID, and Johnson's in oral, wound, and baby care. Kenvue sells these products through traditional retail, e-commerce, and pharmacy channels in over 165 countries. The business model centers on selling branded products at a premium to private-label alternatives, with brand equity reinforced by healthcare professional recommendations. Revenue is driven by unit volumes, pricing, and seasonal factors — particularly cold/flu and allergy seasons, which meaningfully affect the Self Care segment. Kenvue manufactures roughly 60% of its volume in-house, with a regional supply chain structure. Gross margins are healthy at around 60%, but operating margins are more moderate given ongoing investment in advertising, healthcare professional engagement, and innovation. Kenvue runs a restructuring program targeting $350M in annualized savings by 2026, with savings reinvested into brand-building. The company has faced organic growth challenges since separating from Johnson & Johnson in 2023, and new management is focused on simplifying the brand portfolio, strengthening e-commerce, and improving execution. Kenvue's board entered a merger agreement with Kimberly-Clark in late 2025, approved by shareholders in January 2026 and pending regulatory clearance.